1
Clinical Trials associated with Recombinant human anti-RANKL antibody(Zhejiang Hisun Pharmaceutical Co., Ltd.) / Not yet recruitingPhase 1 一项在晚期实体瘤骨转移受试者皮下注射重组抗 RANKL 全人源单克隆抗体注射液的多中心、 开放、 I 期临床研究
[Translation] A multicenter, open-label, phase I clinical study of subcutaneous injection of a recombinant anti-RANKL fully human monoclonal antibody in subjects with advanced solid tumor bone metastases
主要目的: 评价重组抗RANKL全人源单克隆抗体注射液(HS629)单次给药剂量递增、连续给药3次在晚期实体瘤骨转移受试者中的安全性和耐受性。
[Translation] Primary objective: To evaluate the safety and tolerability of a single escalating dose of recombinant anti-RANKL fully human monoclonal antibody injection (HS629) and three consecutive doses in subjects with bone metastases from advanced solid tumors.
100 Clinical Results associated with Recombinant human anti-RANKL antibody(Zhejiang Hisun Pharmaceutical Co., Ltd.)
100 Translational Medicine associated with Recombinant human anti-RANKL antibody(Zhejiang Hisun Pharmaceutical Co., Ltd.)
100 Patents (Medical) associated with Recombinant human anti-RANKL antibody(Zhejiang Hisun Pharmaceutical Co., Ltd.)
100 Deals associated with Recombinant human anti-RANKL antibody(Zhejiang Hisun Pharmaceutical Co., Ltd.)